This study found that 29.1% of Cochrane Skin Group reviews provided strong evidence for or against interventions, showing their potential impact on clinical decision-making.
July 2025 in “The Lancet Regional Health - Southeast Asia”
This Health Policy report outlines the creation of evidence-based clinicalpractice guidelines and referral pathways for managing dermatological conditions in Pakistan's primary care setting, aiming to standardize care and improve patient outcomes.
No results were reported in this guideline paper, which was authored by the Task Force for Guidelines for Virtual Consultations of the ISHRS to provide suggestions on effectively offering virtual consultations in hair restoration practice.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)”
This abstract provides an overview of androgenic alopecia diagnosis and management in general practice, highlighting reliance on clinical evaluation and the use of validated topical and oral treatments to halt disease progression and promote hair regrowth.
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
Sapphire FUE uses sapphire-tipped blades for more precise incisions, but the surgeon's skill and overall procedure management are more crucial for success than the blade type. Both Sapphire and Standard FUE can yield similar results, with recovery influenced more by individual factors and aftercare than the blade used.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.
What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth?No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.
Are there any clinical studies supporting follistatin as a hair loss treatment?There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.